Multiple Sclerosis

Have you or a loved one recently been diagnosed with Multiple Sclerosis (MS)? Are you experiencing weakness, numbness, tingling, movement issues, unstable moods, or memory problems? Call us for a free consultation and see if you qualify.

Below you’ll find the clinical trials we are currently enrolling participants in or will be soon.

• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
  • The purpose of this study is to compare the efficacy and safety of two oral medications (Remibrutinib vs. Teriflunomide) in patients with relapsing MS. This study is for people living with MS who have relapsed in the last year or so.
  • ClinicalTrials.gov Identifier: NCT05156281
• Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)
  • The purpose of this study is to determine the efficacy and safety of the medications ofatumumab and siponimod compared to the medication fingolimod in pediatric patients with MS. This study is for children and adolescents (ages 10-17 years old) living with MS.
  • ClinicalTrials.gov Identifier: NCT04926818
• Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
  • The purpose of this study is to determine the efficacy and safety of the medication Frexalimab in delaying the disability progression of MS. This study is for those living with MS and are 18-60 years old.
  • ClinicalTrials.gov Identifier: NCT06141486
• Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
  • The purpose of this study is to independently measure the annualized relapse rate (ARP) with the administration of the medication Frexalimb compared to the daily oral dose of Teriflunomide. This study is for those with relapsing forms of MS who are 18-55 years old.
  • ClinicalTrial.gov Identifier: NCT06141473